Intuitive Surgical, Inc. shares its unaudited condensed consolidated financial information for the first quarter of 2023, encompassing balance sheets, statements of comprehensive income, and cash flows. The document details current assets, total assets, liabilities, and stockholders' equity, as well as core financial figures such as revenue, cost of revenue, net income, and income from operations. Additionally, accounting policies, business description, and risks like supply chain constraints, inflationary pressures, and the impacts of COVID-19 are outlined. The text delves into specifics like gains and losses, derivatives data, revenue breakdown, system leasing income, and trade accounts receivable, touching on topics such as goodwill, intangible assets, amortization expenses, and legal contingencies like product liability litigation. The company's focus on system sales, leases, and services is emphasized, with mention of key performance obligations and contract assets associated with these arrangements.
The text provides a comprehensive overview of the management's discussion and analysis of the company's financial condition and operations, highlighting the commitment to advancing minimally invasive care through robotic-assisted surgical solutions, particularly with the da Vinci Surgical Systems. It outlines regulatory clearances for various instruments in different markets, sales quotas for surgical robots in China, and reimbursement trends in Japan. The text also discusses the impacts of macroeconomic factors, such as supply chain challenges and the COVID-19 pandemic, and the company's efforts to mitigate risks related to global shortages and pandemic-related disruptions. Furthermore, it delves into recalls and corrective actions in the medical device industry, patient value models for surgeries, and recent business events in the robotic-assisted surgery market, including system demand, placements, and competition.
No significant changes have been observed in the market risk of the company during the first three months of 2023 when compared to the information provided in the Annual Report on Form 10-K for the year 2022.
The text discusses the evaluation of disclosure controls and procedures in accordance with SEC regulations. It mentions that the company maintains controls to ensure timely and accurate reporting of information in Exchange Act reports. The evaluation involved assessing the effectiveness of these controls by the management team, who concluded that they were effective at the reasonable assurance level. Additionally, there were no significant changes in internal control over financial reporting in the most recent fiscal quarter.
The text provides a brief reference to legal proceedings mentioned in Note 8 to the Condensed Consolidated Financial Statements included in a quarterly report.
The text discusses various risks related to the company's business, particularly focusing on macroeconomic conditions, supply chain constraints, reliance on sole-sourced suppliers, and cybersecurity. It mentions how inflation, interest rates, and global recessions can impact demand for products, potentially affecting financial performance. Additionally, supply chain challenges may lead to deferred/canceled procedures, while cybersecurity threats could harm business operations, customer relations, and financial outcomes. The company faces credit risk and market value fluctuations in investments, with the potential for adverse impacts on financial condition. Lastly, the company's investment in early-stage companies poses risks related to research, development, and uncertainties in operating and financial performance, which could influence overall business performance.
There were no unregistered sales of equity securities during the covered period, and the issuer provided details on their stock repurchase activities for the quarter ended March 31, 2023. They repurchased a total of 1,469,856 shares at an average price of $238.14 per share. The issuer had an active stock repurchase program, with an authorized amount of up to $10.0 billion for repurchases, of which $1.1 billion remained available as of March 31, 2023. The program does not have an expiration date.
The text provided states that there are no defaults upon senior securities.
The text provided is a brief mention of a policy or regulation that is not applicable to the specific context it is referring to.
The text provided is a brief statement indicating that there is no additional information to be shared or provided.
The text provided outlines a list of exhibits related to Intuitive Surgical, Inc., including amended corporate documents, certifications by the Chief Executive Officer and Chief Financial Officer pursuant to the Sarbanes-Oxley Act of 2002, materials from the Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, and related filings incorporated by reference. It concludes with the signature section indicating the report was signed on behalf of the company by the Senior Vice President and Chief Financial Officer.
